Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. Some patients with HCC are diagnosed with macrovascular invasion (MVI), which is associated with a poorer prognosis. In Taiwan, sorafenib is the first-line therapy for patients with advanced HCC. However, the ef...

Full description

Bibliographic Details

Published in:	Current Oncology
Main Authors:	Che-Jui Chang, Wei-Fan Hsu, Long-Bin Jeng, Hsueh-Chou Lai, Shih-Chao Hsu, Te-Hung Chen, Hung-Wei Wang, Cheng-Yuan Peng
Format:	Article
Language:	English
Published:	MDPI AG 2023-11-01
Subjects:	sorafenib hepatocellular carcinoma macrovascular invasion post-operation
Online Access:	https://www.mdpi.com/1718-7729/30/12/737